Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas

Lung Cancer

Volumn 81, Issue 1, 2013, Pages 117-122

  Dauphin, Maryline ^a,b   Barbe, Coralie ^b   Lemaire, Sarah ^b   Nawrocki Raby, Béatrice ^a   Lagonotte, Eymeric ^a   Delepine, Gonzague ^b   Birembaut, Philippe ^a,b   Gilles, Christine ^c   Polette, Myriam ^a,b  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

EMT; Non small cell lung carcinomas; Tumour invasion; Vimentin

Indexed keywords

CYTOKERATIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELLULAR DISTRIBUTION; CLINICAL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SARCOMATOID CARCINOMA; TUMOR CELL; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84879080694     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.03.011     Document Type: Article

References (28)

1. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428.
2. Tomaskovic-Crook E., Thompson E.W., Thiery J.P. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009, 11(6):213.
3. Zeisberg M., Neilsson E.G. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119(6):1429-1437.
4. Hendrix M.J., Seftor E.A., Seftor R.E., Trevor K.T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997, 150(2):483-495.
5. Eckes B., Dogic D., Colucci-Guyon E., Wang N., ManiotisA, Ingber D., et al. Impaired mechanical stability, migration and contractile capacity in vimentin deficient fibroblasts. J Cell Sci 1998, 111:1897-1907.
6. Gilles C., Polette M., Zahm J.M., Tournier J.M., Volders L., Foidart J.M., et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 1999, 112:4615-4625.
7. Singh S., Sadacharan S., Su S., Belldegrun A., Persad S., Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003, 63(9):2306-2311.
8. Bonnomet A., Syne L., Brysse A., Feyereisen E., Thompson E.W., Noël A., et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2012, 31(33):3741-3753.
9. Gilles C., Polette M., Piette J., Delvigne A.C., Thompson E.W., Foidart J.M., et al. Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol 1996, 180(2):175-180.
10. Lang S.H., Hyde C., Reid I.N., Hitchcock I.S., Hart C.A., Bryden A.A., et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002, 52(4):253-263.
11. Kokkinos M.I., Wafai R., Wong M.K., Newgreen D.F., Thompson E.W., Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 2007, 185(1-3):191-203.
12. Logullo A.F., Nonogaki S., Pasini F.S., Osorio C.A., Soares F.A., Brentani M.M. Concomitant expression of epithelial mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep 2010, 23(2):313-320.
13. Polette M., Gilles C., De Bentzmann S., Tournier J.M., Birembaut P. Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines. Clin Exp Metast 1998, 16(2):105-112.
14. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 15(11):8686-8698.
15. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor reception inhibition. Cancer Res 2005, 65(20):9455-9462.
16. Al-Saad S., Al-Shibli K., Donnem T., Persson M., Bremmes R.M., Busund L.T. The prognostic impact of NF-KB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 2008, 99(9):1476-1483.
17. Maeda J., Hirano T., Ogiwara A., Akimoto S., Kawakami T., Fukui Y., et al. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer 2008, 98(3):596-603.
18. Soltermann A., Tischler V., Arbogast S., Braun J., Probst-Hensch N., Weder W., et al. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 2008, 14(22):7430-7437.
19. Prudkin L., Liu D.D., Ozburn N.C., Sun M., Behrens C., Tang X., et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 2009, 22(5):668-678.
20. Chikaishi Y., Uramoto H., Tanaka F. The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinomas. Anticancer Res 2011, 31(12):4451-4456.
21. Richardson F., Young G.D., Sennello R., Wolf J., Argast G.M., Mercado P., et al. The evaluation of E-cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res 2012, 32(2):537-552.
22. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.P., Yatabe Y., et al. International association for the study of lung adenocarcinoma/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
23. Pelosi G., Melotti F., Cavazza A., Rossi G., Maisonneuve P., Graziano P., et al. A modified vimentin histogical score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples. Anticancer Res 2012, 32(4):1463-1474.
24. Buisson A.C., Gilles C., Polette M., Zahm J.M., Birembaut P., Tournier J.M. Wound repair-induced expression of stromelysins is associated with the acquisition of a mesenchymal phenotype in human respiratory epithelial cells. Lab Invest 1996, 74(3):658-669.
25. Shintani Y., Okimura A., Sato K., Nakagiri T., Kadota Y., Inoue M., et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg 2011, 92(5):1794-1804.
26. Suda K., Tomizawa K., Fujii M., Murakami H., Osada H., Maehara Y., et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011, 6(7):1152-1161.
27. Qian Q., Wang Q., Zhan P., Peng L., Wei S.Z., Shi Y., et al. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 2010, 28:661-669.
28. Peng W.J., Zhang J.Q., Wang B.X., Pan H.F., Lu M.M., Wang J. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clin Chim Acta 2012, 413:1121-1126.